138 related articles for article (PubMed ID: 38025143)
1. Alpelisib: A Novel Agent for PIK3CA-Related Overgrowth Spectrum.
Nadjkovic K; Lonabaugh K
J Pediatr Pharmacol Ther; 2023; 28(7):590-594. PubMed ID: 38025143
[TBL] [Abstract][Full Text] [Related]
2.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
3. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
Garreta Fontelles G; Pardo Pastor J; Grande Moreillo C
Br J Clin Pharmacol; 2022 Aug; 88(8):3891-3895. PubMed ID: 35146800
[TBL] [Abstract][Full Text] [Related]
4. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).
Canaud G; Lopez Gutierrez JC; Irvine AD; Vabres P; Hansford JR; Ankrah N; Branle F; Papadimitriou A; Ridolfi A; O'Connell P; Turner S; Adams DM
Genet Med; 2023 Dec; 25(12):100969. PubMed ID: 37634128
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.
Singh S; Bradford D; Li X; Mishra-Kalyani PS; Shen YL; Wang L; Zhao H; Xiong Y; Liu J; Charlab R; Kraft J; Khasar S; Miller CP; Rivera DR; Kluetz PG; Pazdur R; Beaver JA; Singh H; Donoghue M
Clin Cancer Res; 2024 Jan; 30(1):23-28. PubMed ID: 37624421
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of Hypoglycemia With Alpelisib in Pediatric Patients With
Nasomyont N; Rutter MM; Backeljauw PF
JCEM Case Rep; 2023 Mar; 1(2):luad027. PubMed ID: 37908459
[TBL] [Abstract][Full Text] [Related]
7. Clinical Response to PI3K-α Inhibition in a Cohort of Children and Adults With
Raghavendran P; Albers SE; Phillips JD; Zarnegar-Lumley S; Borst AJ
J Vasc Anom (Phila); 2022 Mar; 3(1):. PubMed ID: 36284525
[TBL] [Abstract][Full Text] [Related]
8. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.
Morin G; Degrugillier-Chopinet C; Vincent M; Fraissenon A; Aubert H; Chapelle C; Hoguin C; Dubos F; Catteau B; Petit F; Mezel A; Domanski O; Herbreteau G; Alesandrini M; Boddaert N; Boutry N; Broissand C; Han TK; Branle F; Sarnacki S; Blanc T; Guibaud L; Canaud G
J Exp Med; 2022 Mar; 219(3):. PubMed ID: 35080595
[TBL] [Abstract][Full Text] [Related]
9. Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth.
Wenger TL; Ganti S; Bull C; Lutsky E; Bennett JT; Zenner K; Jensen DM; Dmyterko V; Mercan E; Shivaram GM; Friedman SD; Bindschadler M; Drusin M; Perkins JN; Kong A; Bly RA; Dahl JP; Bonilla-Velez J; Perkins JA
Genet Med; 2022 Nov; 24(11):2318-2328. PubMed ID: 36066547
[TBL] [Abstract][Full Text] [Related]
10. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
[TBL] [Abstract][Full Text] [Related]
11. Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome.
López Gutiérrez JC; Lizarraga R; Delgado C; Martínez Urrutia MJ; Díaz M; Miguel M; Triana P
J Pediatr Adolesc Gynecol; 2019 Dec; 32(6):648-650. PubMed ID: 31330249
[TBL] [Abstract][Full Text] [Related]
12. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
13. Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.
Chang DY; Ma WL; Lu YS
Ther Clin Risk Manag; 2021; 17():193-207. PubMed ID: 33707948
[TBL] [Abstract][Full Text] [Related]
14. Undergrowth Of First Toe In PiK3CA-Related Overgrowth Spectrum (PROS).
Triana P; Sarmiento MDC; Rodriguez-Laguna L; Martinez-Glez V; Lopez-Gutierrez JC
Ann Vasc Surg; 2023 Jan; 88():233-238. PubMed ID: 35878698
[TBL] [Abstract][Full Text] [Related]
15. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
[TBL] [Abstract][Full Text] [Related]
16. The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells.
Kirstein AS; Augustin A; Penke M; Cea M; Körner A; Kiess W; Garten A
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31627436
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
18. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the safety and efficacy of currently used treatment modalities in the treatment of patients with PIK3CA-related overgrowth spectrum.
Bernhard SM; Adam L; Atef H; Häberli D; Bramer WM; Minder B; Döring Y; Laine JE; Muka T; Rössler J; Baumgartner I
J Vasc Surg Venous Lymphat Disord; 2022 Mar; 10(2):527-538.e2. PubMed ID: 34358672
[TBL] [Abstract][Full Text] [Related]
20. A Review on Cutaneous and Musculoskeletal Manifestations of CLOVES Syndrome.
Öztürk Durmaz E; Demircioğlu D; Yalınay Dikmen P; Alanay Y; Alanay A; Demirkesen C; Tokat F; Karaarslan E
Clin Cosmet Investig Dermatol; 2022; 15():621-630. PubMed ID: 35444443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]